Literature DB >> 18276940

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.

Roland Diel1, Robert Loddenkemper, Karen Meywald-Walter, Stefan Niemann, Albert Nienhaus.   

Abstract

RATIONALE: Numerous studies have been published on the new Mycobacterium tuberculosis (MTB)-specific IFN-gamma release assays. However, their prognostic value for progression from latent tuberculosis infection (LTBI) to active TB has yet to be established.
OBJECTIVES: To compare the QuantiFERON-TB Gold In-Tube assay (QFT) with the tuberculin skin test (TST) in recently exposed close contacts of active TB cases with respect to their development of TB disease within 2 years.
METHODS: Close contacts (n = 601) of MTB-positive source cases underwent both TST and QFT testing and were subsequently observed for 103 (+/-13.5) weeks. Risk factors for MTB infection were evaluated by multivariate analysis.
MEASUREMENTS AND MAIN RESULTS: For the TST, 40.4% (243/601) of contacts were positive at a 5-mm cutoff, whereas only 66 (11%) were QFT positive. QFT positivity, but not TST, was associated with exposure time (P < 0.0001). Six contacts progressed to TB disease within the 2-year follow-up. All were QFT positive and had declined preventive treatment, equating to a progression rate of 14.6% (6/41) among those who were QFT positive. The progression rate for untreated TST-positive subjects was significantly lower (P < 0.003), at 2.3% (5 of 219), and one subject who progressed was TST negative.
CONCLUSIONS: Results suggest that QFT is a more accurate indicator of the presence of LTBI than the TST and provides at least the same sensitivity for detecting those who will progress to active TB. The high rate of progression to active TB of those who are QFT positive (14.6%), which is far greater than the 2.3% found for those who are TST positive, has health and economic implications for enhanced TB control, particularly if this higher progression rate is seen in studies of other at-risk populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276940     DOI: 10.1164/rccm.200711-1613OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  104 in total

1.  Latent tuberculosis infection screening for laboratory personnel using interferon-γ release assay and tuberculin skin test in Korea: an intermediate incidence setting.

Authors:  Hee-Won Moon; Hanah Kim; Mina Hur; Yeo-Min Yun; Anna Lee
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

2.  Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.

Authors:  Timothy Lahey; Siddharth Sheth; Mecky Matee; Robert Arbeit; C Robert Horsburgh; Lillian Mtei; Todd Mackenzie; Muhammad Bakari; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

3.  Utilization of the QuantiFERON-TB Gold test in a two-step process with the tuberculin skin test to evaluate health care workers for latent tuberculosis.

Authors:  Baha Abdalhamid; Steven H Hinrichs; Jodi L Garrett; Jean M O'Neill; Kristine M Hansen-Cain; Amy A Armbrust; Peter C Iwen
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

Review 4.  Recent advances in testing for latent TB.

Authors:  Neil W Schluger; Joseph Burzynski
Journal:  Chest       Date:  2010-12       Impact factor: 9.410

5.  Tuberculin-specific T cells are reduced in active pulmonary tuberculosis compared to LTBI or status post BCG vaccination.

Authors:  Mathias Streitz; Stephan Fuhrmann; Fiona Powell; Ali Quassem; Laurel Nomura; Holden Maecker; Peter Martus; Hans-Dieter Volk; Florian Kern
Journal:  J Infect Dis       Date:  2010-12-24       Impact factor: 5.226

Review 6.  Striking the right immunological balance prevents progression of tuberculosis.

Authors:  Shachi Pranjal Vyas; Ritobrata Goswami
Journal:  Inflamm Res       Date:  2017-07-15       Impact factor: 4.575

7.  Differences in tuberculin reactivity as determined in a veterans administration employee health screening program.

Authors:  Sanjay R Mehta; Cathy MacGruder; David Looney; Scott Johns; Davey M Smith
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

8.  Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes.

Authors:  Madhukar Pai
Journal:  Nat Rev Microbiol       Date:  2010-01-19       Impact factor: 60.633

9.  The QuantiFERON-TB-GOLD assay for tuberculosis screening in healthcare workers: a cost-comparison analysis.

Authors:  Benjamin D Fox; Mordechai R Kramer; Zohar Mor; Rachel Preiss; Victoria Rusanov; Leonardo Fuks; Nir Peled; Ilanit Haim; Meir Raz; David Shitrit
Journal:  Lung       Date:  2009-10-15       Impact factor: 2.584

10.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.